NEW YORK, July 5, 2018 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Juniper
Pharmaceuticals, Inc. ("JNP" or the "Company") (NASDAQ: JNP) in
connection with the proposed acquisition of the Company by Catalent
Inc. ("CTLT) (NYSE: CTLT). Under the terms of the acquisition
agreement, JNP shareholders will receive $11.50 in cash for each share they own.
WeissLaw is investigating whether JNP's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, the per-share offer price is $8.50 less than the analyst target price of
$20.00.
Additionally, JNP reported record results in its latest
financial release. On May 10,
2018, the Company reported an impressive 30% annual increase
in revenues for its progesterone gel, CRINONE, and a remarkable
increase of 55% year-over-year for revenues relating to its Juniper
Pharma Services.
Finally, the deal is a strategic transaction which CTLT hopes to
leverage to improve its market positioning. According to the
President of CTLT's Oral Drug Delivery, "[JNP's] expertise and
capabilities in pharmaceutical services will further support
[CTLT's] strategic goal to be the comprehensive partner of choice
for pharmaceutical innovators. . . . [JNP]'s proven scientific
expertise in early-phase product development and supply-chain
management will help our customers unlock the full potential of
their molecules and provide better treatments to patients,
faster."
Given these facts, WeissLaw is investigating whether JNP's Board
acted in the best interests of JNP's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own JNP shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the
form on our website,
http://www.weisslawllp.com/juniper-pharmaceuticals-inc/
View original
content:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-juniper-pharmaceuticals-inc-300676767.html
SOURCE WeissLaw LLP